Aspirin increases mortality in diabetic patients without cardiovascular disease: A Swedish record linkage study

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 12, 2009, Pages 1143-1149

  Welin, Lennart ^a   Wilhelmsen, Lars ^b   Björnberg, Arne ^c   Odén, Anders ^d  

^a Lidkoping Hospital   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c Pollex Retro Research   (Sweden)

^d CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

Aspirin; Diabetes; Mortality; Record linkage study

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CONFOUNDING VARIABLE; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; FEMALE; HUMAN; LINKAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; REGISTER; RISK REDUCTION; SWEDEN; THEORETICAL STUDY;

AGE FACTORS; AGED; ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MEDICAL RECORD LINKAGE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; SECONDARY PREVENTION; SWEDEN;

EID: 72449162594     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1828     Document Type: Article

References (18)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of anti-platelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
2. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
3. Sacco M, Pellegrini F, Roncaglioni MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients. Results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26: 3264-3272.
4. Colwell JA. Aspirin for primary prevention of cardiovascular events in diabetes. Diabetes Care 2003; 26: 3349-3350.
5. Ridker PM, Cook NR, Lee IM, et al. A randomised trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-1304.
6. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus. A scientific statement from the American heart Association and the American Diabetes Association. Diabetes Care 2007; 30: 162-172.
7. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007; 28: 88-136.
8. Breslow NE, Day NE. Statistical Methods in Cancer Research, Vol 2. IARC Scientific Publications, No 32: Lyon, 1987; 131-135.
9. Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia 2008; 51: 385-390.
10. Rawlins M. De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet 2008; 372: 2152-2161.
11. Cubbon RM, Gale CP, Rajwani A, et al. Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome. Diabetes Care 2008; 31: 363-365.
12. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
13. Zanchetti A, Hansson L, Dahlöf B, et al. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. J Hypertens 2002; 20: 2301-2307.
14. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Br Med J 2008; 337: a1840. doi:10.1136/bmj.a1840.
15. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes. A randomized controlled trial. JAMA 2008; 300: 2134-2141.
16. Hovens MMC, Van de Laar FA, Cannegier SC, Vandenbroucke JP. Acetylsalicylic acid (Aspirin) for primary prevention of cardiovascular disease in type 2 diabetes mellitus (Protocol). Cochrane Database Syst Rev 2005, 3: CD005446. doi:10.1002/14651858.CD005446.
17. Armitage J, ASCEND: a study of cardiovascular events in diabetes. www.clinicaltrials.gov Identifier: NCT 00135226 [accessed Jan 18, 2009].
18. De Beradis G, Sacco M, Evangelista V, et al. Aspirin and simvastatin combination for cardiovascular events prevention trial in diabetes (ACCEPT-D): design of a randomised study of the efficacy of lowdose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 2007; 8: 21. doi:10.1186/ 1745-6215-8-21.